214370 - Caregen Co., Ltd.

214370 Summary

Biopharma

Stock Price & Overview

₩44,500 +650 (+1.48%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩44,500 ≈ US$32 · Market cap ₩2.4tn (≈ $1.7bn)

214370 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	72.8	82.6	79.2	69.1	59.1	60.3	64.7	51.2	46.5	30.9	—
Cost of Revenue	20.6	27.3	20.8	16.8	13.6	11.7	11.0	18.4	12.3	8.2	—
Gross Profit	52.2	55.3	58.4	52.3	45.5	48.6	53.7	32.9	34.2	22.7	—
Selling, General & Administrative	31.8	21.1	18.0	18.7	17.3	16.7	18.3	13.1	12.3	12.0	—
Operating Income	20.4	34.2	40.4	33.6	28.2	32.0	35.4	19.7	21.9	10.7	—
Finance Income	4.5	6.3	10.0	4.9	5.0	4.7	4.9	4.7	3.1	3.7	—
Finance Costs	2.8	0.6	1.5	4.1	0.8	2.0	0.7	0.5	1.7	0.4	—
Pretax Income	22.4	40.2	49.6	34.5	33.6	36.1	38.9	22.5	23.8	15.5	—
Income Tax Expense	2.3	7.9	9.6	7.2	8.4	4.6	10.9	6.2	5.5	4.2	—
Net Income	20.1	32.3	39.9	27.2	25.2	31.4	28.0	16.3	18.2	11.4	—
Total Comprehensive Income	20.6	32.2	39.7	28.1	25.0	31.4	26.5	17.7	13.7	—	—

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	231.3	240.7	247.3	234.1	226.8	216.6	231.8	218.9	221.8	230.7	—
Current Assets	83.1	96.4	166.4	158.9	149.3	140.6	177.5	166.0	164.1	182.9	—
Cash & Cash Equivalents	8.9	5.1	31.5	5.2	22.2	16.0	21.7	17.5	50.0	70.5	—
Inventories	22.6	18.1	18.7	10.3	6.2	6.5	5.4	5.6	3.7	3.5	—
Trade Receivables	30.0	33.0	13.1	7.0	5.5	4.9	2.6	2.1	3.5	2.4	—
Non-current Assets	148.1	144.3	80.8	75.1	77.4	76.0	54.4	52.9	57.7	47.8	—
Property, Plant & Equipment	125.4	125.6	64.0	60.4	62.1	60.0	40.7	35.6	35.3	26.9	—
Intangible Assets	5.1	4.9	4.7	3.9	3.1	2.2	1.8	1.4	1.3	1.2	—
Total Liabilities	18.8	17.7	20.0	18.1	17.0	11.3	15.0	14.3	11.4	11.0	—
Current Liabilities	8.4	8.1	11.3	10.5	9.8	4.6	9.0	10.6	8.4	8.6	—
Non-current Liabilities	10.4	9.7	8.7	7.6	7.1	6.7	5.9	3.6	3.0	2.4	—
Total Equity	212.5	223.0	227.3	216.0	209.8	205.2	216.9	204.7	210.4	219.7	—
Share Capital	5.4	5.4	5.4	5.4	5.4	5.4	5.4	5.4	5.4	5.4	—
Retained Earnings	275.1	286.1	285.3	273.8	271.4	266.7	270.8	71.7	67.6	65.6	—

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	18.6	13.5	28.6	-27.7	51.9	30.8	69.7	-6.8	47.9	-16.0	—
Cash from Investing Activities	16.5	-4.0	26.1	34.6	-25.1	6.9	-47.1	-3.0	-40.4	2.7	—
Purchase of Property, Plant & Equipment	3.9	65.9	8.2	1.5	3.9	21.1	6.2	2.3	5.6	4.0	—
Cash from Financing Activities	-31.2	-36.4	-28.3	-23.8	-20.5	-43.3	-14.3	-24.4	-23.3	-35.3	—
Dividends Paid	31.1	31.4	28.5	24.5	20.6	34.7	—	12.3	16.4	6.4	—
Net Change in Cash	3.9	-26.9	26.4	-16.9	6.3	-5.6	8.3	-34.2	-15.9	-48.6	—

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	18.8	22.7	16.3	17.1	18.1	21.3	21.4	20.3	20.5	20.4
Cost of Revenue	6.0	7.3	5.9	2.5	5.5	6.6	9.4	2.7	8.9	6.3
Gross Profit	12.8	15.4	10.4	14.6	12.6	14.6	11.9	17.6	11.6	14.2
Selling, General & Administrative	7.6	5.2	17.5	4.7	5.2	4.5	5.8	4.9	5.4	4.9
Operating Income	5.2	10.2	-7.1	9.9	7.4	10.2	6.1	12.7	6.2	9.3
Finance Income	1.8	3.0	2.0	0.3	0.8	1.4	2.5	0.6	0.8	2.8
Finance Costs	1.8	0.2	-0.1	-2.2	4.1	1.0	-0.9	1.5	0.2	0.1
Pretax Income	5.9	13.1	-4.9	12.4	4.2	10.6	9.3	11.8	7.2	11.9
Income Tax Expense	1.6	1.4	-1.6	2.3	-0.6	2.2	4.2	0.1	1.2	2.4
Net Income	4.3	11.7	-3.3	10.2	4.8	8.4	5.1	11.7	6.0	9.5
Total Comprehensive Income	4.2	11.8	-3.0	10.2	5.0	8.5	4.7	11.4	6.5	9.4

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	241.3	245.4	231.3	234.0	234.0	250.0	240.7	236.6	242.3	260.5
Current Assets	92.3	97.3	83.1	88.2	89.7	106.3	96.4	91.6	96.9	180.5
Cash & Cash Equivalents	5.9	13.2	8.9	7.2	21.4	13.0	5.1	18.0	8.4	21.6
Inventories	23.8	23.6	22.6	22.7	18.7	18.0	18.1	21.0	17.6	18.9
Trade Receivables	30.8	34.7	30.0	41.3	37.7	37.8	33.0	26.6	21.6	20.0
Non-current Assets	148.9	148.1	148.1	145.8	144.3	143.6	144.3	145.0	145.5	80.1
Property, Plant & Equipment	124.5	124.7	125.4	125.7	124.6	124.9	125.6	126.4	127.1	63.2
Intangible Assets	5.1	5.0	5.1	5.0	4.9	4.9	4.9	4.9	4.9	4.8
Total Liabilities	22.6	30.9	18.8	18.5	17.1	38.1	17.7	15.9	18.8	43.5
Current Liabilities	11.6	20.3	8.4	8.1	6.9	28.1	8.1	6.7	9.7	34.7
Non-current Liabilities	11.0	10.7	10.4	10.4	10.2	9.9	9.7	9.1	9.1	8.8
Total Equity	218.7	214.5	212.5	215.5	216.9	211.9	223.0	220.7	223.5	217.0
Share Capital	5.4	5.4	5.4	5.4	5.4	5.4	5.4	5.4	5.4	5.4
Retained Earnings	281.3	277.0	275.1	278.4	279.8	275.0	286.1	281.1	281.2	275.1

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	7.7	9.1	6.7	2.6	4.2	5.1	3.2	2.2	0.9	7.2
Cash from Investing Activities	-5.5	-4.5	-5.4	-5.7	24.7	2.8	-14.3	21.9	5.5	-17.2
Purchase of Property, Plant & Equipment	0.8	0.3	0.8	2.1	0.6	0.3	0.1	0.6	65.2	0.0
Cash from Financing Activities	—	—	-0.2	-11.5	-19.6	0.1	-2.4	-14.3	—	—
Dividends Paid	—	—	0.0	11.6	—	—	0.0	11.8	—	—
Net Change in Cash	-7.6	4.6	1.2	-14.5	9.2	7.9	-13.4	9.7	-13.3	-10.0

Consolidated (CFS), from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

214370 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	72.8	-11.8%	+1.8%	+3.8%	—
Operating income	20.4	-40.4%	-15.3%	-8.6%	—
Net income	20.1	-37.8%	-9.6%	-8.6%	—
EPS	₩374	-37.8%	-9.6%	-8.6%	—
Operating cash flow	18.6	+37.8%	—	-9.6%	—
Shareholders' equity	212.5	-4.7%	-0.5%	+0.7%	—

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

214370 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	71.8%	67.0%	73.7%	75.8%	77.1%	80.7%
Operating margin	28.0%	41.5%	51.0%	48.7%	47.7%	53.0%
Net margin	27.6%	39.1%	50.4%	39.4%	42.6%	52.2%
Return on equity	9.2%	14.4%	18.0%	12.8%	12.1%	14.9%
Return on assets	8.5%	13.2%	16.6%	11.8%	11.4%	14.0%
Operating cash flow / revenue	25.5%	16.3%	36.1%	-40.1%	87.8%	51.0%
Capex / revenue	5.3%	79.8%	10.3%	2.2%	6.6%	35.0%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 214370

Symbol	Last Price
141080LigaChem Biosciences Inc.	₩92,000 +4.2%
145020Hugel, Inc.	₩244,000 +1.5%
302440SK Bioscience Co., Ltd.	₩37,900 +0.4%
009420Hanall Biopharma Co., Ltd.	₩54,700 +1.5%
310210Voronoi, Inc.	₩153,000 +3.9%
347850D & D Pharmatech, Inc.	₩49,200 +1.4%
237690ST Pharm Co., Ltd.	₩101,200 +2.2%
226950Olix Pharmaceuticals, Inc.	₩95,900 +4.5%
140410Mezzion Pharma Co., Ltd.	₩65,000 +0.0%
068760Celltrion Pharm, Inc.	₩40,850 +0.0%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.